Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Magenta Therapeutics stock price, quote, forecast and news

MGTA
US55910K1088
A2JPD6

Price

11.76
Today +/-
+0
Today %
+0 %
P

Magenta Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Magenta Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Magenta Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Magenta Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Magenta Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Magenta Therapeutics Stock Price History

DateMagenta Therapeutics Price
10/9/202311.76 undefined
10/6/202312.09 undefined

Magenta Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Magenta Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Magenta Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Magenta Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Magenta Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Magenta Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Magenta Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Magenta Therapeutics’s growth potential.

Magenta Therapeutics Revenue, EBIT and net profit per share

DateMagenta Therapeutics RevenueMagenta Therapeutics EBITMagenta Therapeutics Net Income
2030e233.8 M undefined78.29 M undefined59.4 M undefined
2029e177 M undefined35.75 M undefined29.08 M undefined
2028e114 M undefined-12.34 M undefined-11.14 M undefined
2027e40.06 M undefined-118.82 M undefined-49.5 M undefined
2026e0 undefined0 undefined1.24 M undefined
2025e0 undefined0 undefined1.24 M undefined
2024e0 undefined0 undefined1.24 M undefined
2023e0 undefined-59.05 M undefined-51.36 M undefined
20220 undefined-80.9 M undefined-76.46 M undefined
20210 undefined-74.69 M undefined-71.14 M undefined
20200 undefined-78.7 M undefined-74.94 M undefined
20190 undefined-82.97 M undefined-76.77 M undefined
20180 undefined-59.96 M undefined-57.6 M undefined
20170 undefined-35.73 M undefined-35.51 M undefined
20160 undefined-9.27 M undefined-9.74 M undefined

Magenta Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20162017201820192020202120222023e2024e2025e2026e2027e2028e2029e2030e
0000000000040114177233
------------185.0055.2631.64
---------------
000000000000000
-9-35-59-82-78-74-80-59000-118-123578
------------295.00-10.5319.7733.48
-9-35-57-76-74-71-76-51111-49-112959
-288.8962.8633.33-2.63-4.057.04-32.89-101.96---5,000.00-77.55-363.64103.45
34.372.151.152.3143.9254.9559.3700000000
---------------
Details

Keystats

ⓘ

Revenue and Growth

The Magenta Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Magenta Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2016201720182019202020212022
             
4.551.4142.6145.7148.84176.93112.04
0000000
0000000
0000000
01.12.84.12.693.773.56
4.552.5145.4149.8151.53180.69115.6
0.5210.29.98.317.4629.26
0000000
0000000
0000000
0000000
001.81.81.781.781.78
0.521211.710.099.2431.04
554.5157.4161.5161.62189.93146.65
             
17.992.4000.050.060.06
0.83.1248.3320.6398.31498.21508.11
-9.7-45.2-102.7-179.5-254.43-325.57-402.03
0000-0.02-0.03-0.18
0000000
950.3145.6141.1143.91172.67105.96
1.70.23.52.83.763.042.45
0.646.910.77.127.2712.1
0006005555550
0000000
0000000
2.34.210.414.111.4310.8614.55
0000000
0000000
001.26.26.286.426.14
001.26.26.286.426.14
2.34.211.620.317.7117.2640.69
11.354.5157.2161.4161.62189.93146.65
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Magenta Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Magenta Therapeutics's financial health and stability.

Assets

Magenta Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Magenta Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Magenta Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Magenta Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2016201720182019202020212022
-9-35-57-76-74-71-76
0001121
0000000
1148-1-1-2
111108101110
0000000
0000000
-6-22-41-57-64-59-67
0-2-7-30-10
0-2-911-1043-9
00-844-1044-9
0000000
6000000
471145626833
10711426267892
00-300860
0000000
44786-673-74
-6.67-24.46-49.56-60.16-64.42-60.8-67.4
0000000

Magenta Therapeutics stock margins

The Magenta Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Magenta Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Magenta Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Magenta Therapeutics's sales revenue. A higher gross margin percentage indicates that the Magenta Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Magenta Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Magenta Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Magenta Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Magenta Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Magenta Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Magenta Therapeutics Margin History

Magenta Therapeutics Gross marginMagenta Therapeutics Profit marginMagenta Therapeutics EBIT marginMagenta Therapeutics Profit margin
2030e0 %33.49 %25.41 %
2029e0 %20.19 %16.43 %
2028e0 %-10.83 %-9.77 %
2027e0 %-296.64 %-123.58 %
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %0 %0 %
2023e0 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %

Magenta Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Magenta Therapeutics earnings per share therefore indicates how much revenue Magenta Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Magenta Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Magenta Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Magenta Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Magenta Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Magenta Therapeutics Revenue, EBIT and net profit per share

DateMagenta Therapeutics Sales per ShareMagenta Therapeutics EBIT per shareMagenta Therapeutics Earnings per Share
2030e3.85 undefined0 undefined0.98 undefined
2029e2.92 undefined0 undefined0.48 undefined
2028e1.88 undefined0 undefined-0.18 undefined
2027e0.66 undefined0 undefined-0.82 undefined
2026e0 undefined0 undefined0.02 undefined
2025e0 undefined0 undefined0.02 undefined
2024e0 undefined0 undefined0.02 undefined
2023e0 undefined0 undefined-0.85 undefined
20220 undefined-1.36 undefined-1.29 undefined
20210 undefined-1.36 undefined-1.29 undefined
20200 undefined-1.79 undefined-1.71 undefined
20190 undefined-35.86 undefined-33.18 undefined
20180 undefined-52.17 undefined-50.12 undefined
20170 undefined-16.63 undefined-16.53 undefined
20160 undefined-0.27 undefined-0.28 undefined

Magenta Therapeutics business model

Magenta Therapeutics Inc is a groundbreaking biotechnology company specializing in the development of novel therapies for serious blood disorders. The company uses a unique technology platform based on stem cell transplantation and gene editing to develop innovative therapies that have the potential to improve the lives of millions of people worldwide. Magenta Therapeutics was founded in 2016 by an experienced team of executives and scientists who had previously worked in various biotech companies. The company is headquartered in Cambridge, Massachusetts, USA and has been listed on the NASDAQ stock exchange since 2018. Its business model is based on the development and commercialization of innovative therapies for blood diseases, based on a stem cell technology platform and gene editing technology. These technologies are intended to improve the treatment of blood diseases and enhance the quality of life for patients. Magenta Therapeutics has a comprehensive portfolio of therapy candidates targeting various aspects of stem cell transplantation and gene editing. These therapies aim to reduce the risks and burdens of traditional stem cell transplantation while fully harnessing the potential of stem cell transplantation to cure or alleviate blood diseases. The company has three major business areas: stem cell therapy, gene therapy, and cell therapy. In the context of these business areas, Magenta Therapeutics has already developed several therapy candidates that are currently in various stages of clinical development. The company's work is supported by a variety of financial investors, including some of the most respected names in the biotech industry. Magenta Therapeutics is also actively involved in developing partnerships with other leading companies in the biotechnology industry to further leverage the potential of its platform technology. In conclusion, Magenta Therapeutics is a young and innovative company focused on developing and commercializing new groundbreaking therapies for blood diseases. With its approach of combining stem cell technology and gene editing, the company has the potential to improve the lives of millions of patients with blood diseases while also achieving a significant return for its investors. Magenta Therapeutics is one of the most popular companies on Eulerpool.com.

Magenta Therapeutics SWOT Analysis

Strengths

  • Magenta Therapeutics is known for its cutting-edge approach in developing breakthrough therapeutic solutions.
  • The company's innovative therapies hold the potential to revolutionize the treatment of various diseases and medical conditions.
  • Magenta Therapeutics invests significantly in research and development activities, fostering scientific advancements in the field.
  • The company's robust R&D capabilities enable it to develop novel therapies and stay ahead of the competition.
  • Magenta Therapeutics has established strategic partnerships with renowned organizations, facilitating access to resources and expertise.
  • These partnerships enhance the company's ability to accelerate the development and commercialization of its therapies.

Weaknesses

  • Despite its promising therapies, Magenta Therapeutics has a relatively limited market presence compared to established competitors.
  • Expanding market reach and brand recognition in the highly competitive healthcare industry may pose a challenge.
  • Magenta Therapeutics heavily relies on external funding sources, including grants and partnerships, to support its operations and research initiatives.
  • Financial stability and sustained funding could be a potential weakness for the company's long-term growth and sustainability.

Opportunities

  • The rising demand for advanced therapeutic solutions creates significant opportunities for Magenta Therapeutics to introduce its innovative treatments to the market.
  • The ability to address unmet medical needs reinforces the potential success and adoption of the company's therapies.
  • Magenta Therapeutics can explore international markets and expand its footprint beyond its current geographical presence.
  • Entering new markets offers the potential to increase revenue and diversify the company's customer base.

Threats

  • The healthcare industry is subject to stringent regulations and compliance requirements, which may pose obstacles for Magenta Therapeutics in obtaining necessary approvals and maintaining compliance throughout the product lifecycle.
  • Non-compliance or delays in regulatory processes can significantly impact the company's timelines and performance.
  • Magenta Therapeutics faces intense competition from established pharmaceutical companies, biotech firms, and emerging startups operating in similar therapeutic areas.
  • Staying at the forefront of innovation and continually differentiating its products and services are crucial to maintaining a competitive edge.
  • Economic downturns, market fluctuations, and changes in healthcare policies or reimbursement models can impact the demand and financial viability of Magenta Therapeutics' therapies.
  • Developing contingency plans and maintaining financial resilience is essential for navigating market uncertainties.

Magenta Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Magenta Therapeutics historical P/E ratio, EBIT, and P/S ratio.

Magenta Therapeutics shares outstanding

The number of shares was Magenta Therapeutics in 2023 — This indicates how many shares 59.372 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Magenta Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Magenta Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Magenta Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Magenta Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Magenta Therapeutics.

Magenta Therapeutics list of shareholders

%
Name
Stocks
Change
Date
9.69416 % Tang Capital Management, LLC5,880,9335,880,9332/3/2023
5.73074 % Atlas Venture3,476,536012/31/2022
5.50425 % Alphabet, Inc.3,339,138012/31/2022
5.04116 % Third Rock Ventures, LLC3,058,204-3,700,0002/8/2023
4.94522 % Deep Track Capital LP3,000,000-2,359,00012/31/2022
3.81367 % Millennium Management LLC2,313,552218,21012/31/2022
3.23786 % The Vanguard Group, Inc.1,964,23880612/31/2022
1.55767 % Gardner (Jason M Ph.D.)944,9543,00011/30/2022
1.43189 % Adage Capital Management, L.P.868,65050,00012/31/2022
0.96913 % Renaissance Technologies LLC587,922183,07112/31/2022
1
2
3
4
5
...
10

Magenta Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Beam Therapeutics Stock
Beam Therapeutics
SupplierCustomer0,060,660,900,880,850,33
bluebird bio Stock
bluebird bio
SupplierCustomer-0,070,560,900,920,960,46
Heidelb Ph Stock
Heidelb Ph
SupplierCustomer-0,150,540,09-0,110,780,61
AVROBIO Stock
AVROBIO
SupplierCustomer-0,470,540,970,890,960,60
1

Most common questions regarding Magenta Therapeutics

What values and corporate philosophy does Magenta Therapeutics represent?

Magenta Therapeutics Inc represents a commitment to transformative science in the field of cellular and gene therapies. The company focuses on developing novel medicines to revolutionize the treatment of severe diseases, such as autoimmune disorders, blood cancers, and genetic diseases. Magenta Therapeutics is guided by a patient-centric approach, aiming to provide life-changing therapies that address significant unmet medical needs. The company's corporate philosophy embraces collaboration, innovation, and expertise to accelerate the development of breakthrough therapies. With a focus on precision medicine, Magenta Therapeutics envisions a future where patients can benefit from personalized, curative treatments that improve their quality of life.

In which countries and regions is Magenta Therapeutics primarily present?

Magenta Therapeutics Inc is primarily present in the United States.

What significant milestones has the company Magenta Therapeutics achieved?

Magenta Therapeutics Inc has achieved significant milestones in its journey. The company successfully completed its initial public offering (IPO) in June 2018, raising approximately $100 million in proceeds. Since then, Magenta Therapeutics Inc has made considerable progress in advancing its innovative platform focused on harnessing stem cell biology to develop curative therapies. The company has established strategic partnerships with leading institutions, including the National Institutes of Health (NIH), to accelerate the development of its products. Magenta Therapeutics Inc has also initiated clinical trials for its candidates, aiming to address critical unmet needs in stem cell transplant and gene therapy. These achievements highlight the company's commitment to revolutionizing the field of regenerative medicine.

What is the history and background of the company Magenta Therapeutics?

Magenta Therapeutics Inc is a leading biotechnology company specializing in developing transformative medicines for patients with debilitating diseases. Founded in 2016, the company has quickly made significant strides in the field of regenerative medicine. Magenta Therapeutics aims to revolutionize stem cell transplantation by harnessing the power of stem cells to deliver curative therapies for blood and immune system diseases, such as multiple sclerosis, leukemia, and certain genetic disorders. With its cutting-edge research, novel technologies, and strategic partnerships, Magenta Therapeutics is at the forefront of advancing the field of regenerative medicine, providing hope for patients in need of life-changing treatments.

Who are the main competitors of Magenta Therapeutics in the market?

The main competitors of Magenta Therapeutics Inc in the market include other companies operating in the field of biotechnology and cell therapy. Some prominent competitors of Magenta Therapeutics Inc may include companies like bluebird bio, Novartis AG, CRISPR Therapeutics, and Sangamo Therapeutics, among others. These companies also focus on developing innovative therapies and technologies for various indications, potentially competing with Magenta Therapeutics Inc in the pursuit of breakthrough treatments.

In which industries is Magenta Therapeutics primarily active?

Magenta Therapeutics Inc is primarily active in the biotechnology industry.

What is the business model of Magenta Therapeutics?

Magenta Therapeutics Inc's business model revolves around developing innovative therapies for patients with autoimmune diseases, blood cancers, and genetic diseases through the use of stem cell transplantation. The company focuses on harnessing the power of stem cell biology and gene editing technologies to create durable and curative treatments. Magenta Therapeutics Inc aims to provide patients with safer and more effective therapies by improving the transplantation process and reducing the need for toxic treatments. The company's research and development efforts are dedicated to advancing clinical pipeline candidates and expanding the potential applications of stem cell transplantation in various disease areas.

What is the P/E ratio of Magenta Therapeutics 2024?

The Magenta Therapeutics P/E ratio is 564.19.

What is the P/S ratio of Magenta Therapeutics 2024?

The Magenta Therapeutics P/S ratio is 0.

What is the AlleAktien quality score of Magenta Therapeutics?

The AlleAktien quality score for Magenta Therapeutics is 1/10.

What is the revenue of Magenta Therapeutics 2024?

The revenue cannot currently be calculated for Magenta Therapeutics.

How high is the profit of Magenta Therapeutics 2024?

The expected Magenta Therapeutics profit is 1.24 M USD.

What is the business model of Magenta Therapeutics

Magenta Therapeutics is a biopharmaceutical company based in Cambridge, USA, focused on developing innovative therapies for life-threatening diseases. The company utilizes proprietary stem cell transplantation technology to expand the potential of hematopoietic stem cells (HSCs) for treating serious illnesses. The business model of Magenta Therapeutics is based on developing products for stem cell transplantation, allowing doctors and patients to treat rare diseases. The company operates in four main areas: research and development, manufacturing, clinical trials, and marketing. Magenta Therapeutics' research and development department is responsible for identifying and developing new therapy approaches based on HSCs. The company has an extensive portfolio of proprietary technologies and IP positions, including a groundbreaking gene editing technology that enables targeted manipulation of specific cells in the body. In the manufacturing sector, Magenta Therapeutics operates its own facility for stem cell processing and isolation. The company has also partnered with other manufacturing companies to support the production of stem cells for clinical trials and patient treatments. Magenta Therapeutics' clinical divisions conduct clinical trials to evaluate the effectiveness and safety of products for stem cell transplantation. The company has conducted several clinical studies and plans to conduct more in the near future. Finally, Magenta Therapeutics also has its own marketing department responsible for promoting products for stem cell transplantation. The company has agreements with insurers, hospitals, and clinics to facilitate patient access to its products. Magenta Therapeutics has focused on developing three main products targeting stem cell transplantation. The first product is a gene therapy approach called MGTA-456, which selectively manipulates HSCs to improve engraftment rates and patient survival after stem cell transplantation. The second product is a therapy called MGTA-117, which stimulates the growth of HSCs in the blood and promotes red blood cell production. MGTA-117 has the potential to revolutionize the treatment of patients with anemia and other hematological diseases. Finally, Magenta Therapeutics is also developing a third product called MGTA-145, which aims to use HSCs for treating autoimmune diseases. MGTA-145 has the potential to improve the treatment of patients with severe autoimmune diseases such as multiple sclerosis. In summary, Magenta Therapeutics' business model is focused on developing innovative stem cell transplantation products to help patients with serious illnesses. The company has extensive expertise in researching, developing, manufacturing, and marketing stem cell products and has a portfolio of proprietary technologies and IP positions that differentiate it from other companies in the industry.

What is the Magenta Therapeutics dividend?

Magenta Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Magenta Therapeutics pay dividends?

The dividend cannot currently be calculated for Magenta Therapeutics or the company does not pay out a dividend.

What is the Magenta Therapeutics ISIN?

The ISIN of Magenta Therapeutics is US55910K1088.

What is the Magenta Therapeutics WKN?

The WKN of Magenta Therapeutics is A2JPD6.

What is the Magenta Therapeutics ticker?

The ticker of Magenta Therapeutics is MGTA.

How much dividend does Magenta Therapeutics pay?

Over the past 12 months, Magenta Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Magenta Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Magenta Therapeutics?

The current dividend yield of Magenta Therapeutics is .

When does Magenta Therapeutics pay dividends?

Magenta Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Magenta Therapeutics?

Magenta Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Magenta Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Magenta Therapeutics located?

Magenta Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Magenta Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Magenta Therapeutics from 9/11/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/11/2024.

When did Magenta Therapeutics pay the last dividend?

The last dividend was paid out on 9/11/2024.

What was the dividend of Magenta Therapeutics in the year 2023?

In the year 2023, Magenta Therapeutics distributed 0 USD as dividends.

In which currency does Magenta Therapeutics pay out the dividend?

The dividends of Magenta Therapeutics are distributed in USD.

All fundamentals about Magenta Therapeutics

Our stock analysis for Magenta Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Magenta Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.